Join
Live feed
·
PRReleasevia Quantisnow
Alaunos Therapeutics Inc. logo

Alaunos Therapeutics Announces Positive Preclinical Proof-of-Concept Data for ALN1003, a Differentiated Non-Hormonal Oral Treatment for Obesity and Related Metabolic Disorders

ByQuantisnow·Wall Street's wire, on your screen.
TCRT· Alaunos Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track TCRT (Alaunos Therapeutics Inc.) and more on Quantisnow.